الفهرس 
Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
SCE analysis has come into use as a sensitive mean of
monitoring DNA damage and genetic impairment. Chromosomal
changes and breakage were descried in many congenital and
acquired diseases. Congenital diseases such as (xeroderma
pigmentation, fanconia anaemia, ataxia telangiectasia and Bloom’s
.syndrome), connective tissue diseases (SLE, RA, scleroderma and
Behcet diseases).
This study was done to identify frequency of SCE in SLE, RA
and scleroderma patients and relation between SCE frequency and
activity of the diseases. The effects of using immunosuppressive
drugs on seE.
Forty patients were suffering from connective tissue diseases
(15 SLE, 15 RA, 10 scleroderma) and 10 normal subjects were taken
as control group.
All patients and control group were subjected to clinical
examination, laboratory investigation and detection of the number of
SCE. The results were tabulated, graphed and statistically studied.
The number of SCE statistically increased in SLE and also in RA. In
scleroderma, seE increased compared to control group.
The number of SCE more in SLE than RA and scleroderma.
There is correlation between number of SCE and diseases activities
and age of patients. The use of immunosuppressive drugs increase
number of SCE and SCE increased with cyclophosphamide more
than azathioprine and the least one is methotrexate.
from this results we conclude that:
1- The aetiology of increased number of SCE may be due to genetic
factors which may cause the connective tissue diseases and DNA
repair defect.
2- Activity of diseases Increase the number of SCE due to the
presence of antibodies which may cause damage to DNA.
3- The age of the patients increases the number of SCE due to
prolonged exposure to exogenous and endogenous mutant factors.
4- Therapeutic alkylating agents and other cytotoxic drugs induce
chromosomal damage and DNA repair defect and SCE increased
with cyclophosphamide more than azathioprine and the least one
is methotraxate.